EP. 2 First-line and Subsequent Treatment Strategies for Unresectable/Metastatic Melanoma: A Patient Profile
EP. 7 Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Patient Profile Revisited
EP. 8 Second-line Treatment Strategies for BRAF-mutant Metastatic Melanoma: Additional Patient Scenarios
November 19th, 2026EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical CancersThe EC approved every-6-week maintenance dosing and shorter 350-mg infusions for cemiplimab across all 6 EU indications.Read more
November 18th, 2026NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.Read more